JNJ 75348780
Alternative Names: JNJ-75348780; JNJ-8780Latest Information Update: 31 Oct 2024
Price :
$50 *
At a glance
- Originator TeneoBio
- Developer Janssen Biotech
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 31 Oct 2024 JNJ 75348780 is still in phase I trial for Chronic-lymphocytic-leukaemia (Second-line therapy or greater) in Australia, France, South Korea, Taiwan, Israel, USA, Spain, United Kingdom (SC) (NCT04540796)
- 31 Oct 2024 JNJ 75348780 is still in phase I trials for phase I for Non-Hodgkin's-lymphoma (Second-line therapy or greater) in Australia, France, South Korea, Taiwan, Israel, USA, Spain, United Kingdom (SC) (NCT04540796)
- 28 Oct 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Late-stage disease, Combination therapy, Second-line therapy or greater) in Taiwan (IV) (NCT06660563)